A groundbreaking new study has unveiled that the significant variation in antibody immunity from one person to another is a primary driver in determining which influenza (flu) strains successfully dominate within a human population. The research, published today as a Reviewed Preprint in eLife, provides a novel high-throughput methodology that shifts the scientific perspective on how flu viruses evolve and spread. By analyzing large-scale antibody responses, the study offers a compelling new framework for understanding population-level immunity, a finding that experts suggest will be of vital interest to immunologists, virologists, vaccine developers, and those tasked with mathematical modeling of infectious disease transmission.
The influenza virus is characterized by its remarkable ability to accumulate mutations, a survival mechanism that allows it to evade the antibodies generated by the human immune system following previous infections or vaccinations. This evolutionary "arms race" is the fundamental reason why humans can be reinfected with the flu multiple times throughout their lives and why health authorities must regularly update vaccine formulations to maintain their efficacy against shifting viral targets. Because the human immune response is deeply personal—shaped by a lifetime of different viral encounters and vaccination histories—the landscape of immunity within a population is far from uniform.
“Differences in infection and vaccination histories within a group of people mean that population immunity to a specific variant of the flu is highly varied,” explains co-lead author Caroline Kikawa, an MD/PhD student in the Department of Genome Sciences at the University of Washington and the Division of Basic Sciences and Computational Biology Program at the Fred Hutch Cancer Center. According to Kikawa, the challenge in studying this phenomenon has historically been technical. Conventional laboratory methods used to quantify antibody levels are notoriously slow, labor-intensive, and limited in the number of samples they can process at any given time. This bottleneck has made it difficult for researchers to observe the broader picture of how individual antibody diversity dictates the evolutionary trajectory of emerging flu strains.
To overcome these limitations, Kikawa, co-lead author Andrea Loes, a staff scientist and lab manager in the laboratory of senior author Jesse Bloom, and their colleagues developed an innovative high-throughput neutralization assay. This method allows researchers to measure how effectively individual serum samples—the component of blood that contains antibodies—can neutralize a diverse panel of influenza viruses. The term "high-throughput" refers to the system’s capacity to process thousands of data points simultaneously, a major departure from traditional, low-volume assays.
The research team engineered a library of viruses expressing 78 distinct hemagglutinin (HA) proteins derived from flu viruses circulating in 2023, as well as several recent vaccine strains. Hemagglutinin is the viral surface protein that the immune system primarily recognizes and targets; however, it is also the component that mutates most rapidly to escape detection. To keep track of these variants, the researchers tagged each virus with a unique genetic "barcode." By mixing these barcoded viruses with serum samples and utilizing advanced Illumina sequencing, the team was able to precisely quantify how effectively each individual’s antibodies neutralized each specific virus.
The scope of the data collection was substantial. The researchers measured neutralization titers—the quantitative measure of the concentration of antibodies required to neutralize a virus—against 78 distinct flu variants. By using 150 serum samples collected from both children and adults during the 2023 season, the team generated more than 11,000 individual titer measurements. This provided a remarkably detailed, high-resolution snapshot of the state of population immunity at the dawn of the 2023–2024 flu season.
The resulting data revealed a startling breadth of variation in neutralization responses across the study participants. In children, for instance, the responses were highly polarized; some samples showed robust, broad neutralization against nearly all tested strains, while others demonstrated significantly weaker responses. While adults generally exhibited a more consistent baseline of immunity compared to the children, they still displayed considerable individual variation, suggesting that even in mature populations, the immune landscape is far from homogenous.
One notable finding was that the highest rates of neutralization were found in a specific subset of children. This observation aligns with the long-standing scientific hypothesis that neutralizing antibody responses are typically strongest against the strains encountered during the earliest years of life—a concept sometimes referred to as "original antigenic sin" or immunological imprinting. Alternatively, the researchers noted that children are frequently more exposed to circulating flu viruses, which may provide more recent immunological "boosting" compared to the adult cohorts. Regardless of the precise mechanism, these findings underscore the fact that influenza immunity is fundamentally personalized, reflecting a unique history of biological encounters.
To determine how this granular variation influences the virus on a population level, the researchers performed a statistical comparison between their measured neutralization titers and the growth rates of the various viral strains throughout the 2023 flu season. Utilizing a multinomial logistic regression model, they analyzed how the frequency of each flu strain fluctuated over time, comparing these shifts to the proportion of serum samples that exhibited low neutralization titers against each specific virus.
The results were striking: the strains that achieved the greatest evolutionary success—spreading most rapidly through the population—were precisely those that escaped neutralization in a higher fraction of the collected sera. In essence, the virus was more likely to grow in frequency when a high percentage of the population possessed titers below a critical threshold of protection. This finding suggests that when a significant portion of individuals has weak immunity against a specific strain, that strain gains a competitive advantage, allowing it to flourish and dominate.
Crucially, this relationship between immune escape and viral success was only apparent when the researchers utilized data from individual serum samples. When the team performed the same analysis using pooled serum samples—a method frequently used in some existing viral surveillance systems to estimate population-level immunity—the predictive power vanished. This indicates that pooled measurements, while convenient, likely mask the extreme variations in immunity that actually drive viral evolution. By averaging the results, surveillance systems may fail to capture the "weak links" in a population’s armor that the virus exploits to gain a foothold.
“Our findings show that individual-level immune variation, not just average immunity across the population, is a key factor in determining which flu strains are most successful,” says Loes. This realization suggests that to truly predict the future of influenza, researchers must look closer at the individual diversity that constitutes the collective immune landscape.
While the study represents a significant leap forward, the researchers remain cautious about the generalizability of their current dataset. The samples were obtained from a somewhat limited geographic and demographic range, with most of the pediatric samples originating from a single hospital in Seattle, while the adult samples were drawn from specific vaccinated cohorts in Philadelphia and Australia. Because of this, the authors acknowledge that the dataset may not fully capture the global patterns of immunity that exist across vastly different populations, environments, and vaccination landscapes.
Nevertheless, the study stands as one of the most comprehensive investigations to date linking human antibody immunity to the real-world success of influenza virus strains. “This is one of the largest datasets linking human antibody immunity to the success of flu virus strains in a population,” says senior author Jesse Bloom, an HHMI Investigator and Professor in the Basic Sciences Division and Herbold Computational Biology Program at the Fred Hutch Cancer Center, who also serves as an Affiliate Professor of Genome Sciences at the University of Washington.
Bloom believes that this work provides a vital, scalable framework for researchers to begin parsing how diverse immune histories dictate the complex path of viral evolution. As surveillance systems continue to evolve, these high-throughput sequencing-based assays could provide a powerful complement to existing methods. By offering a more granular, detailed view of population immunity, such insights could ultimately support more informed, evidence-based decisions regarding vaccine composition, potentially leading to more effective seasonal interventions against one of the world’s most persistent and mutating threats.
